Sign in
Taking people in United StatesPhase 2

Ibuprofen alongside dextrose injections for knee osteoarthritis

Tests ibuprofen versus placebo with dextrose knee injections in adults with knee osteoarthritis.

Key facts

Who runs it
David Grant U.S. Air Force Medical Center
Where
Travis AFB, United StatesSee the site
Trial code
Registry title
The Effect and Safety of Anti-inflammatories and Dextrose Prolotherapy Injections in Treating Knee Osteoarthritis
Status
Recruiting
Phase
Phase 2
People taking part
68 people, planned
Started
31 Mar 2025
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Participants are given Ibuprofen 400 mg to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.
  • Participants are given a placebo to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.
Record updated
24 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with long-lasting knee osteoarthritis in one or both knees. They must be DoD Healthcare beneficiaries registered at David Grant Medical Center (DGMC).

Age
45 to 75 years
Sex
All sexes
Disease stage
Knee osteoarthritis confirmed by exam and X-ray, Kellgren-Lawrence grade 2-3 on knee X-rays from within 2 years. Moderate to severe knee pain (score of 4 or more on a 0-10 scale) for at least 3 months.
Earlier treatment
No knee replacement, meniscus repair or cleaning surgery, or cartilage replacement surgery before. No joint injection (steroid, prolotherapy or platelet rich plasma) in the previous 3 months.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Allergy to dextrose, lidocaine, or sulfite
  • Health problems that rule out NSAID use, such as chronic kidney disease stage II or higher, serious heart disease, history of stomach or gut bleeding, or BMI 40 or more
  • Inflammatory joint disease such as gout, psoriatic arthritis or septic arthritis
  • Large fluid build-up in the knee, or not speaking English

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Must be DoD Healthcare beneficiaries empaneled at DGMC
  • Adults aged 45-75 years with a clinical diagnosis of Knee OA (either unilateral or bilateral) based on clinical and radiographic criteria as defined by the American College of Rheumatology (Altman 1987)
  • Knee radiographs (within 2 years of start date) with Kellgren-Lawrence classification of 2-3
  • Moderate to severe Knee pain for at least 3 months defined as a score of ≥4 using the NPRS (0-10) in response to the question "What is the average level of your left/ right knee pain in the past 3 months?"
  • English speaking
  • Not pregnant
  • Not breastfeeding
  • No allergy to dextrose, lidocaine, or sulfite

Who cannot take part

  • Previous knee replacement surgery
  • Previous meniscus repair/debridement surgery or chondral replacement surgery
  • Current/ongoing medical problems obtained from chart review contraindicating NSAID use to include chronic kidney disease stage II or higher, acute interstitial nephritis, coronary artery disease requiring percutaneous coronary intervention (PCI) or bypass surgery; Major Adverse Coronary Event (MACE), body mass index (BMI) ≥40, inflammatory arthropathy (gouty arthritis, psoriatic arthritis, or septic arthritis), history of GI bleed
  • Allergy to dextrose, lidocaine, or sulfite
  • Any intra-articular injection including steroid, prolotherapy or platelet rich plasms within the previous 3 months
  • Significant effusion as defined by a ballotable patella
  • Pregnancy or breastfeeding
  • Non-English speaking

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 45 and 75 years old?

Where in United States

  • David Grant USAF Medical CenterTravis AFB, United StatesContact: Alexander R Kim, MDTaking people

About the trial

What the trial wants to find out

Our purpose is to expand upon the results of the pilot study performed at David Grant Medical Center (DGMC) which showed that concomitant non-steroidal NSAID use in adults with knee osteoarthritis (OA) undergoing a three-shot dextrose prolotherapy (DPT) injection series did not negate the efficacy of DPT. Additionally, it showed that giving both treatments simultaneously is safe and efficacious. The small sample size and design of the pilot study limited the conclusions that can be drawn on the concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) during DPT treatment.

Read full original descriptionShow less

This is a double-blinded, randomized, controlled trial that includes a subject population of males and females between the ages of 45-75 years who are DoD beneficiaries empaneled at DGMC with a history of chronic, symptomatic knee osteoarthritis in one or both knees, that meet study criteria.

Participants will have study inclusion/exclusion and knee films (within the past 2 years) reviewed by a study investigator to confirm eligibility to participate in the study. Eligible participants will be consented then randomized into treatment groups (ibuprofen, placebo) by the pharmacy. Participants will provide a baseline assessment of pain and dysfunction using the Numeric Pain Rating Scale (NPRS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaires. Participants will then have a series of three injections of 4mL of 25% dextrose mixed with 1% lidocaine into the knee under ultrasound guidance, performed at 0, 4 and 8 weeks (+/- 1 week) in addition to a 7-day supply of the study drug (ibuprofen, placebo) at these time points. NPRS and KOOS scores will be collected at 0, 4, 8 and 12 weeks. During the study period, participants will be counseled to avoid oral analgesics (other than what has been prescribed for them as part of the study) including NSAIDs, acetaminophen, or opioids, in addition to other procedures to treat their knee pain to include other injections, acupuncture, physical therapy, and surgery.

The primary outcome is to determine the effect of concomitant oral ibuprofen vs. placebo use on intra-articular knee injections using hypertonic dextrose and the determine the short and long-term outcomes in each treatment group (ibuprofen, placebo) using the NPRS and KOOS questionnaires to assess pain and function.

The 2 groups in the trial

  • Ibuprofen groupExisting treatment, for comparison

    Treatment: Participants are given Ibuprofen 400 mg to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.

  • Placebo groupPlacebo, for comparison

    Treatment: Participants are given a placebo to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Effect of Non-steroidal Anti-inflammatory Drug (NSAID) Use on the Efficacy of Dextrose Prolotherapy in the Treatment of Knee Osteoarthritis: A Randomized Controlled Trial
Plain-language title
Ibuprofen alongside dextrose injections for knee osteoarthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06911359, who can take part
Record updated
24 November 2025